Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 26 2013Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North"). The Company will transfer its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29, 2013, and the first day of trading on First North will be December 2, 2013.

Erik Penser Bankaktiebolag is engaged as Immune´s Certified Adviser on First North. A Company description has been prepared in accordance with First North´s rules and will be made available on Immune´s website. 

Source:

Immune Pharmaceuticals Inc.

Posted in: Business / Finance

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Georgetown study raises concerns over aspirin's role in breast cancer treatment
Study highlights global fertility decline and its implications for the future
Research quantifies impact of childhood obesity on long-term health and life expectancy
Lancet Commission predicts sharp increase in global prostate cancer cases
New urine-based test improves identification of high-grade prostate cancer
Common HIV drugs linked to reduced Alzheimer's disease risk
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Extended CPAP treatment boosts lung development in premature infants

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
St. Jude researchers unveil mechanisms to block PXR and enhance drug potency